Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Pharma & Biotech

Can Anthropic’s Claude help Bristol Myers Squibb speed up medicine discovery and delivery?

Bristol Myers Squibb is moving AI from pilots to enterprise scale. Claude’s real test is governance, data trust and drug development impact.

Read More
Representative image: Scientists work inside an advanced iPSC biomanufacturing lab as FUJIFILM Cellular Dynamics’ Madison facility highlights growing demand for stem cell manufacturing, regenerative medicine infrastructure and cell therapy scale-up.
Pharma & Biotech

Can FUJIFILM’s Madison facility help solve the scale problem in stem cell manufacturing?

iPSC demand is rising fast. FUJIFILM’s Madison facility tests whether stem cell manufacturing can keep pace with pharma and cell therapy needs.

Read More
Representative image: Scientists review DNA delivery and lipid nanoparticle research in a genetic medicines lab as Eli Lilly’s Engage Bio acquisition highlights the growing race to solve non-viral drug delivery challenges.
Pharma & Biotech

Eli Lilly expands genetic medicines toolkit with Engage Bio’s non-viral DNA delivery system

Eli Lilly’s Engage Bio deal is small by its standards, but DNA delivery may become a big battleground in genetic medicines.

Read More
Representative image: Healthcare workers review treatment supplies in a regional clinic as Gilead Sciences and the World Health Organization renew efforts to expand AmBisome access and strengthen visceral leishmaniasis elimination programmes.
Pharma & Biotech

Why Gilead’s visceral leishmaniasis collaboration with WHO matters beyond drug donation

Gilead’s WHO pact targets kala-azar access, but diagnostics, treatment delivery and East Africa execution will decide the impact.

Read More
Representative image: Researchers review AI-enabled virtual screening data and molecular models in a drug discovery lab as Concept Life Sciences and OpenBench push a success-based model for faster, lower-risk biotech hit validation.
Pharma & Biotech

Concept Life Sciences expands drug discovery model as OpenBench brings AI-enabled screening scale

Biotechs need faster hits with less upfront risk. Concept Life Sciences and OpenBench are testing whether success-based discovery can deliver.

Read More
Representative image: Scientists review antibody-drug conjugate research in an oncology laboratory as Gilead Sciences’ Tubulis acquisition sharpens focus on next-generation ADC platforms, solid tumour pipelines and cancer drug development strategy.
Pharma & Biotech

Why Gilead’s $5bn Tubulis deal could reshape its solid tumour pipeline strategy

Gilead’s Tubulis deal strengthens its ADC pipeline, but oncology execution, safety and clinical proof now decide the upside.

Read More
Pharma & Biotech

Why Recordati’s $12.4bn takeover bid could reshape Italy’s listed pharma landscape

Recordati’s $12.4bn buyout bid tests whether rare disease growth can justify one of Europe’s biggest pharma take-private deals.

Read More
Pharma & Biotech

ImmunityBio ISPOR data show why NMIBC treatment choices are becoming harder to standardize

Bladder cancer care is shifting from survival alone to treatment trade-offs. ImmunityBio’s NMIBC survey shows why preference now matters.

Read More
Representative image of biosimilar development and biologics manufacturing for autoimmune disease treatment, highlighting the Polpharma Biologics and Tuteur licensing deal to expand affordable therapy access across Latin America.
Pharma & Biotech

Can Polpharma Biologics and Tuteur improve access to autoimmune disease biologics in Latin America?

LATAM autoimmune care needs cheaper biologics. Polpharma Biologics and Tuteur are betting a biosimilar deal can shift access.

Read More
Representative image: Enhertu’s EU recommendation could expand HER2 targeted cancer treatment options for patients with previously treated metastatic solid tumors, highlighting the growing role of antibody drug conjugates and precision oncology in advanced cancer care.
Pharma & Biotech

Enhertu nears wider EU approval as HER2 testing moves deeper into solid tumor oncology

Find out how Enhertu’s EU recommendation could reshape HER2 targeted treatment for metastatic solid tumors.

Read More